nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitagliptin—CYP3A4—bone cancer	0.881	1	CbGaD
Sitagliptin—Ill-defined disorder—Cisplatin—bone cancer	0.000536	0.00449	CcSEcCtD
Sitagliptin—Renal failure acute—Epirubicin—bone cancer	0.000534	0.00447	CcSEcCtD
Sitagliptin—Osteoarthritis—Methotrexate—bone cancer	0.000527	0.00441	CcSEcCtD
Sitagliptin—Malaise—Cisplatin—bone cancer	0.000521	0.00437	CcSEcCtD
Sitagliptin—Renal impairment—Epirubicin—bone cancer	0.000518	0.00434	CcSEcCtD
Sitagliptin—Eczema—Doxorubicin—bone cancer	0.000507	0.00425	CcSEcCtD
Sitagliptin—Hypoglycaemia—Epirubicin—bone cancer	0.000505	0.00423	CcSEcCtD
Sitagliptin—Renal failure acute—Doxorubicin—bone cancer	0.000494	0.00414	CcSEcCtD
Sitagliptin—Osteoarthritis—Epirubicin—bone cancer	0.000493	0.00413	CcSEcCtD
Sitagliptin—Pain in extremity—Epirubicin—bone cancer	0.000493	0.00413	CcSEcCtD
Sitagliptin—Myalgia—Cisplatin—bone cancer	0.000492	0.00412	CcSEcCtD
Sitagliptin—Anxiety—Cisplatin—bone cancer	0.00049	0.00411	CcSEcCtD
Sitagliptin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000489	0.00409	CcSEcCtD
Sitagliptin—Discomfort—Cisplatin—bone cancer	0.000486	0.00407	CcSEcCtD
Sitagliptin—Migraine—Epirubicin—bone cancer	0.000485	0.00406	CcSEcCtD
Sitagliptin—Renal impairment—Doxorubicin—bone cancer	0.000479	0.00401	CcSEcCtD
Sitagliptin—Breast disorder—Methotrexate—bone cancer	0.000476	0.00399	CcSEcCtD
Sitagliptin—Face oedema—Epirubicin—bone cancer	0.000476	0.00399	CcSEcCtD
Sitagliptin—Anaphylactic shock—Cisplatin—bone cancer	0.000472	0.00395	CcSEcCtD
Sitagliptin—Infection—Cisplatin—bone cancer	0.000469	0.00393	CcSEcCtD
Sitagliptin—Hypoglycaemia—Doxorubicin—bone cancer	0.000467	0.00391	CcSEcCtD
Sitagliptin—Nervous system disorder—Cisplatin—bone cancer	0.000463	0.00388	CcSEcCtD
Sitagliptin—Blood creatinine increased—Epirubicin—bone cancer	0.000462	0.00387	CcSEcCtD
Sitagliptin—Skin disorder—Cisplatin—bone cancer	0.000458	0.00384	CcSEcCtD
Sitagliptin—Osteoarthritis—Doxorubicin—bone cancer	0.000456	0.00382	CcSEcCtD
Sitagliptin—Pain in extremity—Doxorubicin—bone cancer	0.000456	0.00382	CcSEcCtD
Sitagliptin—Orthostatic hypotension—Epirubicin—bone cancer	0.00045	0.00377	CcSEcCtD
Sitagliptin—Abdominal pain upper—Epirubicin—bone cancer	0.00045	0.00377	CcSEcCtD
Sitagliptin—Migraine—Doxorubicin—bone cancer	0.000449	0.00376	CcSEcCtD
Sitagliptin—Pancreatitis—Methotrexate—bone cancer	0.000446	0.00374	CcSEcCtD
Sitagliptin—Breast disorder—Epirubicin—bone cancer	0.000445	0.00373	CcSEcCtD
Sitagliptin—Nasopharyngitis—Epirubicin—bone cancer	0.000441	0.00369	CcSEcCtD
Sitagliptin—Face oedema—Doxorubicin—bone cancer	0.00044	0.00369	CcSEcCtD
Sitagliptin—Abdominal discomfort—Methotrexate—bone cancer	0.000436	0.00366	CcSEcCtD
Sitagliptin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00043	0.0036	CcSEcCtD
Sitagliptin—Blood creatinine increased—Doxorubicin—bone cancer	0.000427	0.00358	CcSEcCtD
Sitagliptin—Influenza—Epirubicin—bone cancer	0.000426	0.00357	CcSEcCtD
Sitagliptin—Upper respiratory tract infection—Methotrexate—bone cancer	0.000423	0.00354	CcSEcCtD
Sitagliptin—Erectile dysfunction—Methotrexate—bone cancer	0.000419	0.00351	CcSEcCtD
Sitagliptin—Pancreatitis—Epirubicin—bone cancer	0.000418	0.0035	CcSEcCtD
Sitagliptin—Abdominal pain upper—Doxorubicin—bone cancer	0.000417	0.00349	CcSEcCtD
Sitagliptin—Orthostatic hypotension—Doxorubicin—bone cancer	0.000417	0.00349	CcSEcCtD
Sitagliptin—Breast disorder—Doxorubicin—bone cancer	0.000412	0.00345	CcSEcCtD
Sitagliptin—Decreased appetite—Cisplatin—bone cancer	0.00041	0.00344	CcSEcCtD
Sitagliptin—Bronchitis—Epirubicin—bone cancer	0.00041	0.00343	CcSEcCtD
Sitagliptin—Pneumonia—Methotrexate—bone cancer	0.000408	0.00342	CcSEcCtD
Sitagliptin—Nasopharyngitis—Doxorubicin—bone cancer	0.000408	0.00342	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Cisplatin—bone cancer	0.000407	0.00341	CcSEcCtD
Sitagliptin—Infestation NOS—Methotrexate—bone cancer	0.000406	0.0034	CcSEcCtD
Sitagliptin—Infestation—Methotrexate—bone cancer	0.000406	0.0034	CcSEcCtD
Sitagliptin—Depression—Methotrexate—bone cancer	0.000405	0.00339	CcSEcCtD
Sitagliptin—Pain—Cisplatin—bone cancer	0.000403	0.00338	CcSEcCtD
Sitagliptin—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000402	0.00337	CcSEcCtD
Sitagliptin—Renal failure—Methotrexate—bone cancer	0.000399	0.00334	CcSEcCtD
Sitagliptin—Upper respiratory tract infection—Epirubicin—bone cancer	0.000396	0.00332	CcSEcCtD
Sitagliptin—Influenza—Doxorubicin—bone cancer	0.000394	0.0033	CcSEcCtD
Sitagliptin—Feeling abnormal—Cisplatin—bone cancer	0.000389	0.00326	CcSEcCtD
Sitagliptin—Weight increased—Epirubicin—bone cancer	0.000388	0.00325	CcSEcCtD
Sitagliptin—Pancreatitis—Doxorubicin—bone cancer	0.000386	0.00324	CcSEcCtD
Sitagliptin—Hyperglycaemia—Epirubicin—bone cancer	0.000384	0.00322	CcSEcCtD
Sitagliptin—Hepatobiliary disease—Methotrexate—bone cancer	0.000384	0.00322	CcSEcCtD
Sitagliptin—Pneumonia—Epirubicin—bone cancer	0.000382	0.0032	CcSEcCtD
Sitagliptin—Infestation NOS—Epirubicin—bone cancer	0.00038	0.00318	CcSEcCtD
Sitagliptin—Infestation—Epirubicin—bone cancer	0.00038	0.00318	CcSEcCtD
Sitagliptin—Bronchitis—Doxorubicin—bone cancer	0.000379	0.00318	CcSEcCtD
Sitagliptin—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000377	0.00315	CcSEcCtD
Sitagliptin—Renal failure—Epirubicin—bone cancer	0.000373	0.00313	CcSEcCtD
Sitagliptin—Neuropathy peripheral—Epirubicin—bone cancer	0.000372	0.00312	CcSEcCtD
Sitagliptin—Urinary tract infection—Epirubicin—bone cancer	0.000369	0.00309	CcSEcCtD
Sitagliptin—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000366	0.00307	CcSEcCtD
Sitagliptin—Pharyngitis—Methotrexate—bone cancer	0.000362	0.00303	CcSEcCtD
Sitagliptin—Urinary tract disorder—Methotrexate—bone cancer	0.00036	0.00301	CcSEcCtD
Sitagliptin—Hepatobiliary disease—Epirubicin—bone cancer	0.000359	0.00301	CcSEcCtD
Sitagliptin—Weight increased—Doxorubicin—bone cancer	0.000359	0.003	CcSEcCtD
Sitagliptin—Urethral disorder—Methotrexate—bone cancer	0.000357	0.00299	CcSEcCtD
Sitagliptin—Sinusitis—Epirubicin—bone cancer	0.000356	0.00299	CcSEcCtD
Sitagliptin—Hyperglycaemia—Doxorubicin—bone cancer	0.000356	0.00298	CcSEcCtD
Sitagliptin—Pneumonia—Doxorubicin—bone cancer	0.000353	0.00296	CcSEcCtD
Sitagliptin—Infestation NOS—Doxorubicin—bone cancer	0.000351	0.00294	CcSEcCtD
Sitagliptin—Infestation—Doxorubicin—bone cancer	0.000351	0.00294	CcSEcCtD
Sitagliptin—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000348	0.00292	CcSEcCtD
Sitagliptin—Hypersensitivity—Cisplatin—bone cancer	0.000348	0.00291	CcSEcCtD
Sitagliptin—Renal failure—Doxorubicin—bone cancer	0.000345	0.00289	CcSEcCtD
Sitagliptin—Erythema multiforme—Methotrexate—bone cancer	0.000344	0.00289	CcSEcCtD
Sitagliptin—Neuropathy peripheral—Doxorubicin—bone cancer	0.000344	0.00289	CcSEcCtD
Sitagliptin—Urinary tract infection—Doxorubicin—bone cancer	0.000342	0.00286	CcSEcCtD
Sitagliptin—Eye disorder—Methotrexate—bone cancer	0.00034	0.00285	CcSEcCtD
Sitagliptin—Hypoaesthesia—Epirubicin—bone cancer	0.000339	0.00284	CcSEcCtD
Sitagliptin—Asthenia—Cisplatin—bone cancer	0.000338	0.00284	CcSEcCtD
Sitagliptin—Pharyngitis—Epirubicin—bone cancer	0.000338	0.00283	CcSEcCtD
Sitagliptin—Cardiac disorder—Methotrexate—bone cancer	0.000338	0.00283	CcSEcCtD
Sitagliptin—Urinary tract disorder—Epirubicin—bone cancer	0.000337	0.00282	CcSEcCtD
Sitagliptin—Oedema peripheral—Epirubicin—bone cancer	0.000336	0.00281	CcSEcCtD
Sitagliptin—Connective tissue disorder—Epirubicin—bone cancer	0.000335	0.00281	CcSEcCtD
Sitagliptin—Urethral disorder—Epirubicin—bone cancer	0.000334	0.0028	CcSEcCtD
Sitagliptin—Hepatobiliary disease—Doxorubicin—bone cancer	0.000332	0.00278	CcSEcCtD
Sitagliptin—Angiopathy—Methotrexate—bone cancer	0.000331	0.00277	CcSEcCtD
Sitagliptin—Sinusitis—Doxorubicin—bone cancer	0.00033	0.00276	CcSEcCtD
Sitagliptin—Immune system disorder—Methotrexate—bone cancer	0.000329	0.00276	CcSEcCtD
Sitagliptin—Mediastinal disorder—Methotrexate—bone cancer	0.000328	0.00275	CcSEcCtD
Sitagliptin—Diarrhoea—Cisplatin—bone cancer	0.000323	0.0027	CcSEcCtD
Sitagliptin—Erythema multiforme—Epirubicin—bone cancer	0.000322	0.0027	CcSEcCtD
Sitagliptin—Mental disorder—Methotrexate—bone cancer	0.000319	0.00267	CcSEcCtD
Sitagliptin—Eye disorder—Epirubicin—bone cancer	0.000319	0.00267	CcSEcCtD
Sitagliptin—Malnutrition—Methotrexate—bone cancer	0.000317	0.00266	CcSEcCtD
Sitagliptin—Cardiac disorder—Epirubicin—bone cancer	0.000316	0.00265	CcSEcCtD
Sitagliptin—Hypoaesthesia—Doxorubicin—bone cancer	0.000314	0.00263	CcSEcCtD
Sitagliptin—Pharyngitis—Doxorubicin—bone cancer	0.000313	0.00262	CcSEcCtD
Sitagliptin—Urinary tract disorder—Doxorubicin—bone cancer	0.000312	0.00261	CcSEcCtD
Sitagliptin—Oedema peripheral—Doxorubicin—bone cancer	0.000311	0.0026	CcSEcCtD
Sitagliptin—Connective tissue disorder—Doxorubicin—bone cancer	0.00031	0.0026	CcSEcCtD
Sitagliptin—Angiopathy—Epirubicin—bone cancer	0.000309	0.00259	CcSEcCtD
Sitagliptin—Urethral disorder—Doxorubicin—bone cancer	0.000309	0.00259	CcSEcCtD
Sitagliptin—Immune system disorder—Epirubicin—bone cancer	0.000308	0.00258	CcSEcCtD
Sitagliptin—Mediastinal disorder—Epirubicin—bone cancer	0.000307	0.00257	CcSEcCtD
Sitagliptin—Back pain—Methotrexate—bone cancer	0.000307	0.00257	CcSEcCtD
Sitagliptin—Vomiting—Cisplatin—bone cancer	0.0003	0.00251	CcSEcCtD
Sitagliptin—Vision blurred—Methotrexate—bone cancer	0.000299	0.0025	CcSEcCtD
Sitagliptin—Mental disorder—Epirubicin—bone cancer	0.000299	0.0025	CcSEcCtD
Sitagliptin—Erythema multiforme—Doxorubicin—bone cancer	0.000298	0.0025	CcSEcCtD
Sitagliptin—Rash—Cisplatin—bone cancer	0.000297	0.00249	CcSEcCtD
Sitagliptin—Dermatitis—Cisplatin—bone cancer	0.000297	0.00249	CcSEcCtD
Sitagliptin—Malnutrition—Epirubicin—bone cancer	0.000297	0.00249	CcSEcCtD
Sitagliptin—Eye disorder—Doxorubicin—bone cancer	0.000295	0.00247	CcSEcCtD
Sitagliptin—Ill-defined disorder—Methotrexate—bone cancer	0.000294	0.00247	CcSEcCtD
Sitagliptin—Cardiac disorder—Doxorubicin—bone cancer	0.000293	0.00245	CcSEcCtD
Sitagliptin—Flatulence—Epirubicin—bone cancer	0.000292	0.00245	CcSEcCtD
Sitagliptin—Tension—Epirubicin—bone cancer	0.000291	0.00244	CcSEcCtD
Sitagliptin—Nervousness—Epirubicin—bone cancer	0.000288	0.00241	CcSEcCtD
Sitagliptin—Back pain—Epirubicin—bone cancer	0.000287	0.00241	CcSEcCtD
Sitagliptin—Angiopathy—Doxorubicin—bone cancer	0.000286	0.0024	CcSEcCtD
Sitagliptin—Malaise—Methotrexate—bone cancer	0.000286	0.0024	CcSEcCtD
Sitagliptin—Muscle spasms—Epirubicin—bone cancer	0.000285	0.00239	CcSEcCtD
Sitagliptin—Immune system disorder—Doxorubicin—bone cancer	0.000285	0.00239	CcSEcCtD
Sitagliptin—Vertigo—Methotrexate—bone cancer	0.000285	0.00239	CcSEcCtD
Sitagliptin—Mediastinal disorder—Doxorubicin—bone cancer	0.000284	0.00238	CcSEcCtD
Sitagliptin—Nausea—Cisplatin—bone cancer	0.00028	0.00235	CcSEcCtD
Sitagliptin—Vision blurred—Epirubicin—bone cancer	0.00028	0.00234	CcSEcCtD
Sitagliptin—Cough—Methotrexate—bone cancer	0.000277	0.00232	CcSEcCtD
Sitagliptin—Mental disorder—Doxorubicin—bone cancer	0.000276	0.00232	CcSEcCtD
Sitagliptin—Ill-defined disorder—Epirubicin—bone cancer	0.000275	0.00231	CcSEcCtD
Sitagliptin—Malnutrition—Doxorubicin—bone cancer	0.000275	0.0023	CcSEcCtD
Sitagliptin—Flatulence—Doxorubicin—bone cancer	0.000271	0.00227	CcSEcCtD
Sitagliptin—Arthralgia—Methotrexate—bone cancer	0.00027	0.00226	CcSEcCtD
Sitagliptin—Myalgia—Methotrexate—bone cancer	0.00027	0.00226	CcSEcCtD
Sitagliptin—Tension—Doxorubicin—bone cancer	0.000269	0.00226	CcSEcCtD
Sitagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000268	0.00225	CcSEcCtD
Sitagliptin—Malaise—Epirubicin—bone cancer	0.000268	0.00224	CcSEcCtD
Sitagliptin—Discomfort—Methotrexate—bone cancer	0.000267	0.00223	CcSEcCtD
Sitagliptin—Nervousness—Doxorubicin—bone cancer	0.000267	0.00223	CcSEcCtD
Sitagliptin—Vertigo—Epirubicin—bone cancer	0.000267	0.00223	CcSEcCtD
Sitagliptin—Back pain—Doxorubicin—bone cancer	0.000266	0.00223	CcSEcCtD
Sitagliptin—Muscle spasms—Doxorubicin—bone cancer	0.000264	0.00221	CcSEcCtD
Sitagliptin—Cough—Epirubicin—bone cancer	0.000259	0.00217	CcSEcCtD
Sitagliptin—Anaphylactic shock—Methotrexate—bone cancer	0.000259	0.00217	CcSEcCtD
Sitagliptin—Vision blurred—Doxorubicin—bone cancer	0.000259	0.00217	CcSEcCtD
Sitagliptin—Infection—Methotrexate—bone cancer	0.000257	0.00215	CcSEcCtD
Sitagliptin—Hypertension—Epirubicin—bone cancer	0.000256	0.00215	CcSEcCtD
Sitagliptin—Ill-defined disorder—Doxorubicin—bone cancer	0.000255	0.00213	CcSEcCtD
Sitagliptin—Nervous system disorder—Methotrexate—bone cancer	0.000254	0.00213	CcSEcCtD
Sitagliptin—Arthralgia—Epirubicin—bone cancer	0.000253	0.00212	CcSEcCtD
Sitagliptin—Myalgia—Epirubicin—bone cancer	0.000253	0.00212	CcSEcCtD
Sitagliptin—Anxiety—Epirubicin—bone cancer	0.000252	0.00211	CcSEcCtD
Sitagliptin—Skin disorder—Methotrexate—bone cancer	0.000251	0.00211	CcSEcCtD
Sitagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000251	0.0021	CcSEcCtD
Sitagliptin—Discomfort—Epirubicin—bone cancer	0.00025	0.00209	CcSEcCtD
Sitagliptin—Malaise—Doxorubicin—bone cancer	0.000248	0.00207	CcSEcCtD
Sitagliptin—Dry mouth—Epirubicin—bone cancer	0.000247	0.00207	CcSEcCtD
Sitagliptin—Vertigo—Doxorubicin—bone cancer	0.000247	0.00207	CcSEcCtD
Sitagliptin—Anaphylactic shock—Epirubicin—bone cancer	0.000242	0.00203	CcSEcCtD
Sitagliptin—Infection—Epirubicin—bone cancer	0.000241	0.00202	CcSEcCtD
Sitagliptin—Cough—Doxorubicin—bone cancer	0.00024	0.00201	CcSEcCtD
Sitagliptin—Nervous system disorder—Epirubicin—bone cancer	0.000238	0.00199	CcSEcCtD
Sitagliptin—Hypertension—Doxorubicin—bone cancer	0.000237	0.00199	CcSEcCtD
Sitagliptin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000236	0.00198	CcSEcCtD
Sitagliptin—Skin disorder—Epirubicin—bone cancer	0.000235	0.00197	CcSEcCtD
Sitagliptin—Insomnia—Methotrexate—bone cancer	0.000234	0.00196	CcSEcCtD
Sitagliptin—Myalgia—Doxorubicin—bone cancer	0.000234	0.00196	CcSEcCtD
Sitagliptin—Arthralgia—Doxorubicin—bone cancer	0.000234	0.00196	CcSEcCtD
Sitagliptin—Anxiety—Doxorubicin—bone cancer	0.000233	0.00195	CcSEcCtD
Sitagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000232	0.00195	CcSEcCtD
Sitagliptin—Discomfort—Doxorubicin—bone cancer	0.000231	0.00194	CcSEcCtD
Sitagliptin—Somnolence—Methotrexate—bone cancer	0.00023	0.00193	CcSEcCtD
Sitagliptin—Dry mouth—Doxorubicin—bone cancer	0.000229	0.00192	CcSEcCtD
Sitagliptin—Dyspepsia—Methotrexate—bone cancer	0.000228	0.00191	CcSEcCtD
Sitagliptin—Decreased appetite—Methotrexate—bone cancer	0.000225	0.00189	CcSEcCtD
Sitagliptin—Anaphylactic shock—Doxorubicin—bone cancer	0.000224	0.00188	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Methotrexate—bone cancer	0.000223	0.00187	CcSEcCtD
Sitagliptin—Fatigue—Methotrexate—bone cancer	0.000223	0.00187	CcSEcCtD
Sitagliptin—Infection—Doxorubicin—bone cancer	0.000223	0.00187	CcSEcCtD
Sitagliptin—Pain—Methotrexate—bone cancer	0.000221	0.00185	CcSEcCtD
Sitagliptin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000221	0.00185	CcSEcCtD
Sitagliptin—Nervous system disorder—Doxorubicin—bone cancer	0.00022	0.00184	CcSEcCtD
Sitagliptin—Insomnia—Epirubicin—bone cancer	0.000219	0.00184	CcSEcCtD
Sitagliptin—Skin disorder—Doxorubicin—bone cancer	0.000218	0.00182	CcSEcCtD
Sitagliptin—Somnolence—Epirubicin—bone cancer	0.000215	0.0018	CcSEcCtD
Sitagliptin—Feeling abnormal—Methotrexate—bone cancer	0.000213	0.00179	CcSEcCtD
Sitagliptin—Dyspepsia—Epirubicin—bone cancer	0.000213	0.00179	CcSEcCtD
Sitagliptin—Gastrointestinal pain—Methotrexate—bone cancer	0.000212	0.00177	CcSEcCtD
Sitagliptin—Decreased appetite—Epirubicin—bone cancer	0.000211	0.00176	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Epirubicin—bone cancer	0.000209	0.00175	CcSEcCtD
Sitagliptin—Fatigue—Epirubicin—bone cancer	0.000209	0.00175	CcSEcCtD
Sitagliptin—Pain—Epirubicin—bone cancer	0.000207	0.00174	CcSEcCtD
Sitagliptin—Constipation—Epirubicin—bone cancer	0.000207	0.00174	CcSEcCtD
Sitagliptin—Urticaria—Methotrexate—bone cancer	0.000206	0.00172	CcSEcCtD
Sitagliptin—Abdominal pain—Methotrexate—bone cancer	0.000205	0.00171	CcSEcCtD
Sitagliptin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000204	0.00171	CcSEcCtD
Sitagliptin—Insomnia—Doxorubicin—bone cancer	0.000203	0.0017	CcSEcCtD
Sitagliptin—Feeling abnormal—Epirubicin—bone cancer	0.0002	0.00167	CcSEcCtD
Sitagliptin—Somnolence—Doxorubicin—bone cancer	0.000199	0.00167	CcSEcCtD
Sitagliptin—Gastrointestinal pain—Epirubicin—bone cancer	0.000198	0.00166	CcSEcCtD
Sitagliptin—Dyspepsia—Doxorubicin—bone cancer	0.000197	0.00165	CcSEcCtD
Sitagliptin—Decreased appetite—Doxorubicin—bone cancer	0.000195	0.00163	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000194	0.00162	CcSEcCtD
Sitagliptin—Fatigue—Doxorubicin—bone cancer	0.000193	0.00162	CcSEcCtD
Sitagliptin—Urticaria—Epirubicin—bone cancer	0.000192	0.00161	CcSEcCtD
Sitagliptin—Constipation—Doxorubicin—bone cancer	0.000192	0.00161	CcSEcCtD
Sitagliptin—Pain—Doxorubicin—bone cancer	0.000192	0.00161	CcSEcCtD
Sitagliptin—Abdominal pain—Epirubicin—bone cancer	0.000191	0.0016	CcSEcCtD
Sitagliptin—Hypersensitivity—Methotrexate—bone cancer	0.000191	0.0016	CcSEcCtD
Sitagliptin—Asthenia—Methotrexate—bone cancer	0.000186	0.00156	CcSEcCtD
Sitagliptin—Feeling abnormal—Doxorubicin—bone cancer	0.000185	0.00155	CcSEcCtD
Sitagliptin—Gastrointestinal pain—Doxorubicin—bone cancer	0.000183	0.00154	CcSEcCtD
Sitagliptin—Hypersensitivity—Epirubicin—bone cancer	0.000178	0.0015	CcSEcCtD
Sitagliptin—Urticaria—Doxorubicin—bone cancer	0.000178	0.00149	CcSEcCtD
Sitagliptin—Abdominal pain—Doxorubicin—bone cancer	0.000177	0.00148	CcSEcCtD
Sitagliptin—Diarrhoea—Methotrexate—bone cancer	0.000177	0.00148	CcSEcCtD
Sitagliptin—Asthenia—Epirubicin—bone cancer	0.000174	0.00146	CcSEcCtD
Sitagliptin—Dizziness—Methotrexate—bone cancer	0.000171	0.00143	CcSEcCtD
Sitagliptin—Diarrhoea—Epirubicin—bone cancer	0.000166	0.00139	CcSEcCtD
Sitagliptin—Hypersensitivity—Doxorubicin—bone cancer	0.000165	0.00138	CcSEcCtD
Sitagliptin—Vomiting—Methotrexate—bone cancer	0.000165	0.00138	CcSEcCtD
Sitagliptin—Rash—Methotrexate—bone cancer	0.000163	0.00137	CcSEcCtD
Sitagliptin—Dermatitis—Methotrexate—bone cancer	0.000163	0.00137	CcSEcCtD
Sitagliptin—Headache—Methotrexate—bone cancer	0.000162	0.00136	CcSEcCtD
Sitagliptin—Asthenia—Doxorubicin—bone cancer	0.000161	0.00135	CcSEcCtD
Sitagliptin—Dizziness—Epirubicin—bone cancer	0.00016	0.00134	CcSEcCtD
Sitagliptin—Vomiting—Epirubicin—bone cancer	0.000154	0.00129	CcSEcCtD
Sitagliptin—Nausea—Methotrexate—bone cancer	0.000154	0.00129	CcSEcCtD
Sitagliptin—Diarrhoea—Doxorubicin—bone cancer	0.000153	0.00128	CcSEcCtD
Sitagliptin—Rash—Epirubicin—bone cancer	0.000153	0.00128	CcSEcCtD
Sitagliptin—Dermatitis—Epirubicin—bone cancer	0.000153	0.00128	CcSEcCtD
Sitagliptin—Headache—Epirubicin—bone cancer	0.000152	0.00127	CcSEcCtD
Sitagliptin—Dizziness—Doxorubicin—bone cancer	0.000148	0.00124	CcSEcCtD
Sitagliptin—Nausea—Epirubicin—bone cancer	0.000144	0.00121	CcSEcCtD
Sitagliptin—Vomiting—Doxorubicin—bone cancer	0.000143	0.00119	CcSEcCtD
Sitagliptin—Rash—Doxorubicin—bone cancer	0.000141	0.00118	CcSEcCtD
Sitagliptin—Dermatitis—Doxorubicin—bone cancer	0.000141	0.00118	CcSEcCtD
Sitagliptin—Headache—Doxorubicin—bone cancer	0.00014	0.00118	CcSEcCtD
Sitagliptin—Nausea—Doxorubicin—bone cancer	0.000133	0.00112	CcSEcCtD
